Asset profile
Laromestrocel · Lomecel-B
Cell therapy
Evidence outlook · lead readout
CLEARMIND (NCT05233774) · Mild Alzheimer's Disease
The completed lead evidence is positive, with design limits that temper confidence; the rationale below says which.
CLEARMIND (NCT05233774): This trial was randomized, blinded, and placebo-controlled, but it enrolled only 50 patients and was designed primarily to test safety rather than a clinical outcome; cognitive measures were assessed only as secondary endpoints. The safety objective was met, but the small size and safety-focused design mean this trial does not by itself demonstrate a clinical benefit.
Also in development:Hypoplastic Left Heart Syndrome
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
63 competitors in this universe: 2 direct rivals (same mechanism and indication), 1 same-class, 60 same-indication; 31 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Laromestrocel (Lomecel-B): this drug | Phase 2 | Cell therapy | Mesenchymal stem cell therapy | ||
| AstroStem | Phase 2 | Cell therapy | Mesenchymal stem cell therapy | ||
| RB-ADSC | Phase 2 | Cell therapy | Mesenchymal stem cell therapy | ||
| MitoCell | Phase 1 | Cell therapy | Mesenchymal stem cell therapy | ||
| Benzgalantamine (Zunveyl) | Approved | Small molecule | Acetylcholinesterase/nicotinic receptor (prodrug) | ||
| Brexpiprazole (Rexulti) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | ||
| Dextromethorphan / Bupropion (Auvelity) | Approved | Small molecule | sigma-1/NMDA | ||
| Donanemab (Kisunla) | Approved | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | ||
| Lecanemab (Leqembi) | Approved | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | ||
| Xanomeline / Trospium Chloride (Cobenfy) | Approved | Small molecule | Muscarinic M1/M4 receptor (agonist/antagonist combination) | ||
| ACP-204 | Phase 3 | Small molecule | Serotonin 5-HT2A receptor (antagonist / inverse agonist) | ||
| AR1001 | Phase 3 | Small molecule | PDE5 | ||
| Bezisterim | Phase 3 | Small molecule | ERK/NF-kB inflammatory | ||
| Blarcamesine | Phase 3 | Small molecule | Sigma-1 receptor / muscarinic receptor (dual) | ||
| Buntanetap | Phase 3 | Small molecule | APP/tau/alpha-synuclein/TDP-43 (translation) | ||
| Cerebrolysin | Phase 3 | Peptide | Multi-target (ginsenoside) |
…and 48 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.